Kassouf W et al., 2007-10: In 12 dogs, intraprostatic injection of 1:10 diluted 1% methylene blue with gadolinium mapped injectate distribution across 3-, 10- and 20-core schemes and validated MRI as a distribution measure for intraprostatic gene therapy and drug delivery.
Four dogs in each group were injected with a 1:10 dilution of 1% methylene blue and gadolinium-diethylenetriamine pentaacetic acid using 3, 10, and 20-core injection schemes.
Kassouf W et al., 2007-10: In 12 dogs, intraprostatic injection of 1:10 diluted 1% methylene blue with gadolinium mapped injectate distribution across 3-, 10- and 20-core schemes and validated MRI as a distribution measure for intraprostatic gene therapy and drug delivery. C4. Study type: animal (canine orthotopic prostate), methods/validation. N: 12 dogs (4 per injection scheme). Country: USA (MD Anderson Cancer Center, Houston). Methylene blue: 1:10 dilution of 1% solution injected intraprostatically with gadolinium-DTPA; 3, 10 or 20 cores per prostate; animals killed after MRI. Funder: non-US government/other support per PublicationType. Conflicts: none declared. Comparator: MRI distribution vs gross methylene blue staining (Pearson r = 0.97). Study type: animal.
